

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax 0091-11-26498341, 26494708, Phone: 0091-11-46181100, 46109900 Email: nandita.singh@jagsonpal.com; cs@jagsonpal.com CIN No. L74899DL1978PLC009181

Date: May 13th, 2022

To, To, The Department of Corporate Services-The Department of Corporate Services-Listing Listing National Stock Exchange of India Ltd BSE Ltd, Exchange Plaza, C-1, Block G, Phiroze Jeejeebhoy Towers, Dalai Street Bandra Kuria Complex, Mumbai-400 001 Bandra (E) Mumbai - 400 051 Symbol: JAGSNPHARM

Scrip Code: 507789

Sub: Annual Disclosure pursuant to SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018

Dear Sirs.

Pursuant to SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, please find enclosed herewith Annual Disclosure for the Financial Year 2021-22 as Annexure-A.

It is informed that there was no Incremental Borrowing applicable to the Company during the Financial Year 2021-22 as per the explanation provided in the aforesaid circular.

Kindly take the above mentioned on your record.

For JAGSONPAL PHARMACEUTICALS LIMITED

NEW DELHI * 03

Nandita Singh **Company Secretary and Compliance Officer**

Factory: 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953

Annexure-A

Annual Disclosure to be made by an entity identified as a Large Corporate as per SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018

- 1. Name of the Company:- Jagsonpal Pharmaceuticals Limited
- 2. CIN:- L74899DL1978PLC009181
- 3. Report filed for FY:- 2021-22
- 4. Details of the Current block (all figures in Rs crore):-

S. No.	Particulars	Details
i.	2-year block period (Specify financial years)	2021-22, 2022-23
ii,	Incremental borrowing done in FY (T) (a)	0.00
iii.	Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)	0.00
iv.	Actual borrowing done through debt securities in FY (T) (c)	0.00
V	Shortfall in the borrowing through debt securities, if any, for FY (T-1) carried forward to FY (T). (d)	0.00
vi.	Quantum of (d), which has been met from (c) (e)	0.00
vii	Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) {after adjusting for any shortfall in borrowing for FY (T-1) which was carried forward to FY (T)} (f)= (b)-[(c)-(e)] {If the calculated value is zero or negative, write "nil"}	0.00

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore):

S. No.	Particulars	Details
i.	2-year Block period (Specify financial years)	2020-21, 2021-22
ii.	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}#	0.00

(d) and (e) are same as mentioned at 4 (v) and 4 (vi) of this Annexure.

For JAGSONPAL PHARMACEUTICALS LIMITED

NEW DELH Nandita Singh

Company Secretary and Compliance Officer